COMMUNIQUÉS West-GlobeNewswire

VIVUS to Present at Biotech Showcase on January 9, 2019

27/12/2018 - 13:30

CAMPBELL, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on [...]

Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference

27/12/2018 - 13:05

SALT LAKE CITY, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 37 th annual J.P. Morgan [...]

Blood donors encouraged to keep appointments to help patients this holiday season

27/12/2018 - 13:00

OTTAWA, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services is asking donors to keep their appointments to give blood during the holidays to help ensure blood and blood products are available for those in need. On [...]

La Société canadienne du sang encourage les donneurs à respecter leur rendez-vous

27/12/2018 - 13:00

OTTAWA, 27 déc. 2018 (GLOBE NEWSWIRE) -- La Société canadienne du sang demande aux donneurs qui ont un rendez-vous pendant la période des Fêtes de respecter leur engagement. Il est important que les donneurs se [...]

G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

27/12/2018 - 13:00

RESEARCH TRIANGLE PARK, N.C., Dec. 27, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will [...]

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

27/12/2018 - 13:00

BERKELEY HEIGHTS, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]

Axsome Therapeutics Provides Year End 2018 Clinical Update

27/12/2018 - 13:00

FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019 Phase 3 results of AXS-05 in treatment resistant depression [...]

Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee

27/12/2018 - 13:00

BRIDGEWATER, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Gregory Cowan, a [...]

HEXO reaches construction and licensing milestones for its massive 1 million sq. ft. greenhouse – on time and on budget

27/12/2018 - 12:30

GATINEAU, Quebec, Dec. 27, 2018 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO ) has reached a construction and licensing milestone with the first phase of its 1 million sq. ft. greenhouse expansion [...]

HEXO atteint des jalons concernant sa serre d’un million de pieds carrés – construction et octroi de licence – selon les délais et le budget prévus

27/12/2018 - 12:30

GATINEAU, Québec, 27 déc. 2018 (GLOBE NEWSWIRE) -- HEXO Corp (« HEXO » ou la « Société ») (TSX: HEXO ) a franchi une étape importante touchant la première phase de l’agrandissement d’un million de pieds carrés de sa [...]

Transactions in relation to share buyback program

27/12/2018 - 11:58

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Organic electronics: Bio-on presents Eloxel, to develop the use of bioplastics in the electronics sector. At his side Kartell, strategic partner

27/12/2018 - 10:27

ELOXEL is born ( organic electronics for electronics ) the new company created by Bio-on to exploit the patents destined to revolutionize the world of electronics through the use of bioplastics. The aim is to enable [...]

Financial calendar of JSC Olainfarm for 2019

27/12/2018 - 08:59

JSC Olainfarm informs that in 2019 submission of financial results is scheduled for the following dates: Unaudited consolidated Annual Report for 2018 – on February 28, 2019; Unaudited consolidated interim financial [...]

Rule 2.9 Announcement

27/12/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 27 December 2018 [...]

TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer

26/12/2018 - 22:05

SAN DIEGO, Dec. 26, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, [...]

IntelGenx Grants Restricted Share Units

26/12/2018 - 22:00

SAINT LAURENT, Quebec, Dec. 26, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTC.QX:IGXT) announced today that the Company’s board of directors granted Restricted [...]

Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine

26/12/2018 - 20:31

FDA Approves VAXELIS (TM) , Sanofi and MSD's Pediatric Hexavalent Combination Vaccine PARIS and KENILWORTH, N.J. - December 26 , 2018 - The U.S. Food and Drug Administration has approved VAXELIS(TM) (Diphtheria and [...]

Sanofi : La FDA approuve VAXELIS(TM), le vaccin combiné hexavalent pédiatrique de Sanofi et MSD

26/12/2018 - 20:31

La FDA approuve VAXELIS (TM) , le vaccin combiné hexavalent pédiatrique de Sanofi et MSD PARIS et KENILWORTH (New Jersey) - Le 26 décembre 2018 - La Food and Drug Administration (FDA) des États-Unis a approuvé VAXELIS( [...]

Alzamend Neuro™ Completes New Management Team for 2019

26/12/2018 - 15:00

Appoints Financial Executive, Kenneth S. Cragun, as New CFO and Treasurer Tampa, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier [...]